A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma

被引：0
|
作者：
Trefzer, U
Weingart, G
Chen, Y
Adrian, K
Audring, H
Winter, H
Guo, YJ
Sterry, W
Walden, P
机构：
[1] Humboldt Univ, Fac Med Charite, Dept Dermatol, D-10098 Berlin, Germany
[2] Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA
来源：
GENE THERAPY OF CANCER | 1998年 / 451卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：519 / 525
页数：7
相关论文
共 50 条
  • [31] Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
    Lau, R
    Wang, F
    Jeffery, G
    Marty, V
    Kuniyoshi, J
    Bade, E
    Ryback, ME
    Weber, J
    JOURNAL OF IMMUNOTHERAPY, 2001, 24 (01): : 66 - 78
  • [32] A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma
    Mudigonda, Tejaswi V.
    Wyman, Kenneth
    Spigel, David R.
    Dahlman, Kimberly B.
    Greco, F. Anthony
    Puzanov, Igor
    Kelley, Mark C.
    Hainsworth, John D.
    Sosman, Jeffrey A.
    Johnson, Douglas B.
    PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (01) : 101 - 103
  • [33] Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma
    Escudier, Bernard
    Lassau, Nathalie
    Angevin, Eric
    Soria, Jean Charles
    Chami, Linda
    Lamuraglia, Michele
    Zafarana, Eric
    Landreau, Veronique
    Schwartz, Brian
    Brendel, Eric
    Armand, Jean-Pierre
    Robert, Caroline
    CLINICAL CANCER RESEARCH, 2007, 13 (06) : 1801 - 1809
  • [34] PHASE-II TRIAL OF MITOLACTOL IN PATIENTS WITH METASTATIC MELANOMA
    MEDINA, W
    KIRKWOOD, JM
    CANCER TREATMENT REPORTS, 1982, 66 (01): : 195 - 196
  • [35] Phase II trial of imatinib mesylate in patients with metastatic melanoma
    K B Kim
    O Eton
    D W Davis
    M L Frazier
    D J McConkey
    A H Diwan
    N E Papadopoulos
    A Y Bedikian
    L H Camacho
    M I Ross
    J N Cormier
    J E Gershenwald
    J E Lee
    P F Mansfield
    L A Billings
    C S Ng
    C Charnsangavej
    M Bar-Eli
    M M Johnson
    A J Murgo
    V G Prieto
    British Journal of Cancer, 2008, 99 : 734 - 740
  • [36] PHASE-II TRIAL OF BISANTRENE IN PATIENTS WITH METASTATIC MELANOMA
    MACKEL, C
    MEYSKENS, FL
    ALBERTS, DS
    CANCER TREATMENT REPORTS, 1986, 70 (08): : 1037 - 1038
  • [37] Phase II trial of imatinib mesylate in patients with metastatic melanoma
    Kim, K. B.
    Eton, O.
    Davis, D. W.
    Frazier, M. L.
    McConkey, D. J.
    Diwan, A. H.
    Papadopoulos, N. E.
    Bedikian, A. Y.
    Camacho, L. H.
    Ross, M. I.
    Cormier, J. N.
    Gershenwald, J. E.
    Lee, J. E.
    Mansfield, P. F.
    Billings, L. A.
    Ng, C. S.
    Charnsangavej, C.
    Bar-Eli, M.
    Johnson, M. M.
    Murgo, A. J.
    Prieto, V. G.
    BRITISH JOURNAL OF CANCER, 2008, 99 (05) : 734 - 740
  • [38] A phase II trial of arsenic trioxide in patients with metastatic melanoma
    Kim, KB
    Bedikian, AY
    Camacho, LH
    Papadopoulos, NE
    McCullough, C
    CANCER, 2005, 104 (08) : 1687 - 1692
  • [39] Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma
    Rohaan, M. W.
    Gomez-Eerland, R.
    Foppen, M. H. Geukes
    van Zon, M.
    de Boer, R.
    Bakker, N. A. M.
    Pronk, L. M.
    Sari, A.
    Mallo, H. A.
    van de Wiel, B. A.
    Lalezari, F.
    Beijnen, J. H.
    Nuijen, B.
    van Tinteren, H.
    van Thienen, J. V.
    Blank, C. U.
    Wilgenhof, S.
    Schumacher, T. N.
    van den Berg, J. H.
    Haanen, J. B. A. G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine
    Cohen, L
    de Moor, C
    Parker, PA
    Amato, RJ
    UROLOGIC ONCOLOGY, 2002, 7 (03): : 119 - 124
12345